Funding for this research was provided by:
National Institute of Neurological Disorders and Stroke (1R01NS092122)
Michael J. Fox Foundation for Parkinson's Research (LRRK2 in immunity)
Academy of Finland (295724, 310835)
Suomen Lääketieteen Säätiö
Helsingin Yliopisto (UAK1014004, UAK1014005, TYH2018224)
Received: 21 August 2020
Accepted: 19 January 2021
First Online: 8 February 2021
Ethics approval and consent to participate
: This study was conducted in accordance with the Declaration of Helsinki and was approved by the ethics committee of the Hospital District of Helsinki and Uusimaa. All participants gave informed consent.
: Not applicable.
: VTEA, PABP, LP, PA, and FS have patents issued (FI127671B & US10139408B2) and pending (US16/186,663 & EP3149205) that are assigned to NeuroBiome Ltd.FS is founder and CEO of NeuroInnovation Oy and NeuroBiome Ltd., is a member of the scientific advisory board and has received consulting fees and stock options from Axial Biotherapeutics.MGT is an advisor to INmune Bio, Longevity Biotech, Prevail Therapeutics, and Weston Garfield Foundation. MGT has patents issued (US Pat. Nos. 7144987B1 and 7244823B2) and pending (US20150239951, WO2019067789, 62/901698, see efiling Ack37193677, 62/905747, see efilingAck37274773) for co-invention of DN-TNFs.